10 research outputs found
The effect of scaffold physical properties on endothelial cell function
Thesis: Ph. D. in Materials Science and Medical Engineering, Harvard-MIT Program in Health Sciences and Technology, February 2010.Cataloged from PDF version of thesis.Includes bibliographical references (pages 135-139).Endothelial cells (EC) are ubiquitous - as vascular epithelial cells they line the inner surface of all vessels and are the contact surface with flowing blood. Macrovascular EC are the first line barrier between flowing blood and mural structures. The microvasculature includes EC-lined vessels that contact virtually every cell in the body. These EC are potent bioregulatory cells, modulating thrombosis, inflammation and control over mural smooth muscle cells and vascular health. The biochemical roles of EC can be retained when cells are embedded within three-dimensional matrices without recapitulation of the full vessel architecture. Within these matrices, surface and structural properties impose a set of forces on the embedded EC. Indeed, substrata pore size and modulus have profound effects on phenotype and function of a range of cell types. In the first part of this work, we examined the effect of pore size, matrix relative density and modulus on matrix-embedded EC growth and secretion and found a greater biological dependence on modulus than pore size or density. In the second part of this work, we examined the effect of isolated changes in modulus on BC growth, secretion of growth regulators, and modulation of smooth muscle cell growth. EC growth is maximal at intermediate moduli over a range from 50 Pa- 1500 Pa. Secretion of heparan sulfate proteoglycans (HSPGs), which inhibit smooth muscle cell growth, is maximal at low moduli and flat at high moduli. Secretion of growth factors such as FGF2 and PDGF-BB were also modulus responsive. Inhibition of smooth muscle cell growth rose as modulus decreased from 510 Pa to 50 Pa and was the result of a balance between increased HSPG secretion and reduced secretion of vasoactive growth factors. Changes in endothelial function correlated with extracellular matrix gene and integrin aP 3 and c41 expression. Changes in the forces experienced by the cell - a change in substrate modulus - cause the cell to alter its ECM and integrin expression in an effort to return the force balance to normal, leading to downstream effects on cell function. While growth stimulatory function largely conserved, growth inhibitory function was altered to a much larger degree. In the final part of this work, we examined the effect of scaffold modulus on EC response to inflammatory stimuli, and attempted to correlate it to changes in smooth muscle cell regulation and integrin expression. While cytokine secretion was independent of modulus, surface expression of ICAM- 1 and VCAM-1, and induction of CD4' T cell proliferation followed a similar pattern to smooth muscle cell inhibition, suggesting that similar mechanisms may be involved in their regulation by substrate modulus. Alteration of scaffold modulus has a profound impact on EC function including growth regulation and inflammatory response. The model offered in this thesis - wherein EC attempt to neutralize changes in environmental force balance by altering ECM and integrin expression, leading to changes in downstream function - offers insight into how environmental changes effect functional changes in ECs.by Sylaja Murikipudi.Ph. D. in Materials Science and Medical Engineerin
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
To address the coronavirus disease 2019 (COVID-19) pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recombinant subunit vaccine, AKS-452, is being developed comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain (SP/RBD) antigen and human IgG1 Fc emulsified in the water-in-oil adjuvant, Montanideâą ISA 720. A single-center, open-label, phase I dose-finding and safety study was conducted with 60 healthy adults (18â65 years) receiving one or two doses 28 days apart of 22.5 ”g, 45 ”g, or 90 ”g of AKS-452 (i.e., six cohorts, N = 10 subjects per cohort). Primary endpoints were safety and reactogenicity and secondary endpoints were immunogenicity assessments. No AEs â„ 3, no SAEs attributable to AKS-452, and no SARS-CoV-2 viral infections occurred during the study. Seroconversion rates of anti-SARS-CoV-2 SP/RBD IgG titers in the 22.5, 45, and 90 ”g cohorts at day 28 were 70%, 90%, and 100%, respectively, which all increased to 100% at day 56 (except 89% for the single-dose 22.5 ”g cohort). All IgG titers were Th1-isotype skewed and efficiently bound mutant SP/RBD from several SARS-CoV-2 variants with strong neutralization potencies of live virus infection of cells (including alpha and delta variants). The favorable safety and immunogenicity profiles of this phase I study (ClinicalTrials.gov: NCT04681092) support phase II initiation of this room-temperature stable vaccine that can be rapidly and inexpensively manufactured to serve vaccination at a global scale without the need of a complex distribution or cold chain
The effect of substrate modulus on the growth and function of matrix-embedded endothelial cells
Endothelial cells (EC) are potent bioregulatory cells, modulating thrombosis, inflammation and control over mural smooth muscle cells and vascular health. The biochemical roles of EC are retained when cells are embedded within three-dimensional (3D) denatured collagen matrices. Though substrate mechanics have long been known to affect cellular morphology and function and 3D-EC systems are increasingly used as therapeutic modalities little is known about the effect of substrate mechanics on EC in these 3D systems. In this work, we examined the effect of isolated changes in modulus on EC growth and morphology, extracellular matrix gene expression, modulation of smooth muscle cell growth, and immunogenicity. EC growth, but not morphology was dependent on scaffold modulus. Increased scaffold modulus reduced secretion of smooth muscle cell growth inhibiting heparan sulfate proteoglycans (HSPGs), but had no effect on secreted growth factors, resulting in a loss of smooth muscle cell growth inhibition by EC on high modulus scaffolds. Expression of ICAM-1, VCAM-1 and induction of CD4[superscript +] T cell proliferation was reduced by increased scaffold modulus, and correlated with changes in integrin α5 expression. Expression of several common ECM proteins by EC on stiffer substrates dropped, including collagen IV(α1), collagen IV(α5), fibronectin, HSPGs (perlecan and biglycan). In contrast, expression of elastin and TIMPs were increased. This work shows even modest changes in substrate modulus can have a significant impact on EC function in three-dimensional systems. The mechanism of these changes is not clear, but the data presented here within suggests a model wherein EC attempt to neutralize changes in environmental force balance by altering ECM and integrin expression, leading to changes in effects on downstream signaling and function.National Institutes of Health (U.S.) (R01 GM49039)Else Kroner-Fresenius Stiftung (P36/07//A45/07
An ultraâlongâacting recombinant insulin for the treatment of diabetes mellitus in cats
BackgroundTreatment of diabetes mellitus (DM) in cats typically requires insulin injections q12h-q24h, posing a major compliance barrier for caregivers. Novel treatments enabling decreased injection frequency while maintaining safety are highly desirable. Insulin fused with feline immunoglobulin fragment crystallizable (Fc) has an ultra-long plasma half-life because it recycles through cells where it is protected from proteolysis.HypothesisGlycemic control can be achieved in diabetic cats with a recombinant fusion protein of a synthetic insulin and feline Fc (AKS-267c) administered SC weekly.AnimalsFive cats with spontaneous DM.MethodsCats previously controlled using insulin glargine q12h were transitioned to once-weekly injection of AKS-267c. The dose of AKS-267c was titrated weekly for 7âweeks based on continuous glucose monitoring. Clinical signs, body weight, fructosamine concentrations, and mean interstitial glucose concentrations (IG) were compared between baseline (week 0, on insulin glargine) and the last week of treatment. Data were assessed for normality and compared using parametric or nonparametric paired tests (as appropriate).ResultsAfter 7âweeks of once-weekly injections, compared to baseline, there were no significant changes in clinical signs, body weight (median [range] gain, 0.1 kg [-0.1 toâ+0.7]; P = .5), fructosamine (-60âmmol/L [-338âtoâ+206]; P = .6), and mean IG concentrations (change = -153âmmol/L [-179âtoâ+29]; P = .3), and no adverse reactions were reported.ConclusionSuccessful control of clinical signs and maintenance of glycemia was achieved with this once-weekly novel insulin treatment. The efficacy and safety of this novel formulation should be further assessed in a large clinical trial
Ultraâlongâacting recombinant insulin for the treatment of diabetes mellitus in dogs
Abstract Background For the treatment of diabetes mellitus (DM) in dogs, novel insulins with decreased injection frequency while maintaining safety and efficacy are desirable. Insulin fused with immunoglobulinâfragmentâcrystallizable (Fc) has an ultraâlong plasma halfâlife because it recycles through cells, protected from proteolysis. Hypothesis Glycemic control can be achieved in diabetic dogs with a recombinant fusion protein of a synthetic insulin and canine Fc (AKSâ218d) administered subcutaneously onceâweekly. Animals Five clientâowned dogs with naturally occurring DM. Methods Prospective clinical trial in dogs with DM that were recruited from the UC Davis Veterinary Teaching Hospital and local veterinary clinics. Dogs previously controlled using intermediateâacting insulin q12h were transitioned to onceâweekly injections of a preliminary construct identified as AKSâ218d. The dose of AKSâ218d was titrated weekly for 8âweeks based on clinical response and continuous interstitial glucose monitoring. Clinical signs, body weight, serum fructosamine concentrations, and mean interstitial glucose concentrations (IG) over the preceding week were compared between baseline (before AKSâ218d) and during the last week of treatment. Data were compared using nonparametric paired tests. Results Onceâweekly AKSâ218d, compared to baseline twiceâdaily insulin therapy, resulted in no significant changes in clinical signs, median (range) body weight (+0.4Â kg [â0.5â1.1]; PÂ =Â .6), fructosamine concentration (â75âmmol/L [â215 to +126]; PÂ =Â .4), or mean IG (+81âmg/dL [â282 to +144]; PÂ =Â .8). No adverse reactions were reported. Conclusion Control of clinical signs, body weight, and maintenance of glycemia was achieved with this onceâweekly novel insulin construct in 4 of 5 dogs
An antigen-specific immunotherapeutic, AKS-107, deletes insulin-specific B cells and prevents murine autoimmune diabetes
IntroductionThe antigen-presenting cell function of insulin-reactive B cells promotes type 1 diabetes (T1D) in non-obese diabetic (NOD) mice by stimulating pathogenic T cells leading to destruction of insulin-producing ÎČ-cells of pancreatic islets.Methods/ResultsTo target insulin-reactive B cells, AKS-107, a human IgG1 Fc molecule fused with human insulin A and B chains, was engineered to retain conformational insulin epitopes that bound mouse and human B cell receptors but prevented binding to the insulin metabolic receptor. AKS-107 Fc-mediated deletion of insulin-reactive B cells was demonstrated via ex vivo and in vivo experiments with insulin-reactive B cell receptor transgenic mouse strains, VH125Tg/NOD and Tg125(H+L)/NOD. As an additional immune tolerance feature, the Y16A mutation of the insulin B(9-23) dominant T cell epitope was engineered into AKS-107 to suppress activation of insulin-specific T cells. In mice and non-human primates, AKS-107 was well-tolerated, non-immunogenic, did not cause hypoglycemia even at high doses, and showed an expectedly protracted pharmacokinetic profile. AKS-107 reproducibly prevented spontaneous diabetes from developing in NOD and VH125Tg/NOD mice that persisted for months after cessation of treatment, demonstrating durable immune tolerance.DiscussionThese preclinical outcomes position AKS-107 for clinical development in T1D prevention settings
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine
AKS-452, a subunit vaccine comprising an Fc fusion of the ancestral wild-type (WT) SARS-CoV-2 virus spike protein receptor binding domain (SP/RBD), was evaluated without adjuvant in a single cohort, non-randomized, open-labelled phase II study (NCT05124483) at a single site in The Netherlands for safety and immunogenicity. A single 90 ”g subcutaneous booster dose of AKS-452 was administered to 71 adults previously primed with a registered mRNA- or adenovirus-based vaccine and evaluated for 273 days. All AEs were mild and no SAEs were attributable to AKS-452. While all subjects showed pre-existing SP/RBD binding and ACE2-inhibitory IgG titers, 60â68% responded to AKS-452 via â„2-fold increase from days 28 to 90 and progressively decreased back to baseline by day 180 (days 28 and 90 mean fold-increases, 14.7 ± 6.3 and 8.0 ± 2.2). Similar response kinetics against RBD mutant proteins (including omicrons) were observed but with slightly reduced titers relative to WT. There was an expected strong inverse correlation between day-0 titers and the fold-increase in titers at day 28. AKS-452 enhanced neutralization potency against live virus, consistent with IgG titers. Nucleocapsid protein (Np) titers suggested infection occurred in 66% (46 of 70) of subjects, in which only 20 reported mild symptomatic COVID-19. These favorable safety and immunogenicity profiles support booster evaluation in a planned phase III universal booster study of this room-temperature stable vaccine that can be rapidly and inexpensively manufactured to serve vaccination at a global scale without the need of a complex distribution or cold chain.</p
Recommended from our members
Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcÎłR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanideâą ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain
A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452
Background: Previous interim data from a phase I study of AKS-452, a subunit vaccine comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor binding domain (SP/RBD) emulsified in the water-in-oil adjuvant, Montanideâą ISA 720, suggested a good safety and immunogenicity profile in healthy adults. This phase I study was completed and two dosing regimens were further evaluated in this phase II study. Methods: This phase II randomized, open-labelled, parallel group study was conducted at a single site in The Netherlands with 52 healthy adults (18 â 72 years) receiving AKS-452 subcutaneously at one 90 ”g dose (cohort 1, 26 subjects) or two 45 ”g doses 28 days apart (cohort 2, 26 subjects). Serum samples were collected at the first dose (day 0) and at days 28, 56, 90, and 180. Safety and immunogenicity endpoints were assessed, along with induction of IgG isotypes, cross-reactive immunity against viral variants, and IFN-Îł T cell responses. Results: All AEs were mild/moderate (grades 1 or 2), and no SAEs were attributable to AKS-452. Seroconversion rates reached 100% in both cohorts, although cohort 2 showed greater geometric mean IgG titers that were stable through day 180 and associated with enhanced potencies of SP/RBD-ACE2 binding inhibition and live virus neutralization. AKS-452-induced IgG titers strongly bound mutant SP/RBD from several SARS-CoV-2 variants (including Omicrons) that were predominantly of the favorable IgG1/3 isotype and IFN-Îł-producing T cell phenotype. Conclusion: These favorable safety and immunogenicity profiles of the candidate vaccine as demonstrated in this phase II study are consistent with those of the phase I study (ClinicalTrials.gov: NCT04681092) and suggest that a total of 90 ”g received in 2 doses may offer a greater duration of cross-reactive neutralizing titers than when given in a single dose